Vaccine

Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial ResultsApellis Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results

Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results

Reported $781.4 million in full year 2024 revenues, representing 97% year-over-year growth SYFOVRE® (pegcetacoplan injection) full year 2024 net product…

4 months ago
Rapid Micro Biosystems Reports Fourth Quarter and Full Year 2024 Financial Results and Provides 2025 GuidanceRapid Micro Biosystems Reports Fourth Quarter and Full Year 2024 Financial Results and Provides 2025 Guidance

Rapid Micro Biosystems Reports Fourth Quarter and Full Year 2024 Financial Results and Provides 2025 Guidance

Reports record fourth quarter 2024 total revenue of $8.2 million, representing 30% growth compared to fourth quarter 2023; recurring revenue…

4 months ago
Nxera Pharma Enters Agreement with Holling to Commercialize Daridorexant in TaiwanNxera Pharma Enters Agreement with Holling to Commercialize Daridorexant in Taiwan

Nxera Pharma Enters Agreement with Holling to Commercialize Daridorexant in Taiwan

Daridorexant is a potential best-in-class treatment in the high-growth, dual orexin antagonist class of medicines treating sleep disorders, such as…

4 months ago
Novavax to Participate in Upcoming March Investor ConferencesNovavax to Participate in Upcoming March Investor Conferences

Novavax to Participate in Upcoming March Investor Conferences

GAITHERSBURG, Md., Feb. 27, 2025 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), today announced that the management team will participate in…

4 months ago
Anivive Sponsors 69th Annual Coccidioidomycosis Study Group MeetingAnivive Sponsors 69th Annual Coccidioidomycosis Study Group Meeting

Anivive Sponsors 69th Annual Coccidioidomycosis Study Group Meeting

Hosted by Arizona State University and Mayo ClinicAnivive provides $50,000 in travel awardsLeading global experts pioneering novel fungal vaccines, therapeutics…

4 months ago
A Decade of Black Excellence: Finalists of Anticipated Top Blacks in Healthcare (TBH) Awards AnnouncedA Decade of Black Excellence: Finalists of Anticipated Top Blacks in Healthcare (TBH) Awards Announced

A Decade of Black Excellence: Finalists of Anticipated Top Blacks in Healthcare (TBH) Awards Announced

CHICAGO, Feb. 27, 2025 /PRNewswire/ -- BlackDoctor.org (BDO), a nationally recognized leader in Black health, announces finalists of its 10th…

4 months ago
Ocugen, Inc. Announces FDA Alignment on Phase 2/3 Pivotal Confirmatory Clinical Trial for Modifier Gene Therapy Candidate OCU410ST for Stargardt DiseaseOcugen, Inc. Announces FDA Alignment on Phase 2/3 Pivotal Confirmatory Clinical Trial for Modifier Gene Therapy Candidate OCU410ST for Stargardt Disease

Ocugen, Inc. Announces FDA Alignment on Phase 2/3 Pivotal Confirmatory Clinical Trial for Modifier Gene Therapy Candidate OCU410ST for Stargardt Disease

MALVERN, Pa., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader…

4 months ago
Avance Biosciences™ Registers with CLIA, Expanding Clinical Trial Testing CapabilitiesAvance Biosciences™ Registers with CLIA, Expanding Clinical Trial Testing Capabilities

Avance Biosciences™ Registers with CLIA, Expanding Clinical Trial Testing Capabilities

HOUSTON, Feb. 26, 2025 /PRNewswire/ -- Avance Biosciences, a leading provider of high-quality analytical and bioanalytical services for the pharmaceutical…

4 months ago
IMUNON Announces New Immunogenicity Data from Phase 1 Clinical Trial of Its DNA Vaccine in Treatment of COVID-19IMUNON Announces New Immunogenicity Data from Phase 1 Clinical Trial of Its DNA Vaccine in Treatment of COVID-19

IMUNON Announces New Immunogenicity Data from Phase 1 Clinical Trial of Its DNA Vaccine in Treatment of COVID-19

Results of IMNN-101 Proof-of-Concept study demonstrate persistent immunogenicity in trial participants and further validate PlaCCine® technology IMNN-101 induced 2- to…

4 months ago
Alveo Technologies and Royal GD Form Long-Term Partnership to Expand Joint Offerings for Rapid, Molecular Animal Diagnostics at Point-of-NeedAlveo Technologies and Royal GD Form Long-Term Partnership to Expand Joint Offerings for Rapid, Molecular Animal Diagnostics at Point-of-Need

Alveo Technologies and Royal GD Form Long-Term Partnership to Expand Joint Offerings for Rapid, Molecular Animal Diagnostics at Point-of-Need

Their first co-developed product, Alveo Sense™ Poultry Avian Influenza was introduced in the EU in late 2024 and is now…

4 months ago